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Abstract
Background: Estimates of travel-related illness have focused predominantly on populations 
from highly developed countries visiting low- or middle-income countries, yet travel to and within 
high-income countries is very frequent. Despite being a top international tourist destination, few 
sources describe the spectrum of infectious diseases acquired among travelers to the United States.
Corresponding author: Rhett J. Stoney, MPH, Travelers’ Health Branch, Division of Global Migration and Quarantine, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE MS V18-2, Atlanta, GA, USA 30329, uyn2@cdc.gov.
Author contributions
Study Design: RJS, DHE, PK, DHH, MPG, EGK, ML, PG, PLL, KL, ES, MJS, CL
Data collection: PK, MPG, EGK, ML, PG, PLL, KL, ES, MJS, CL
Analysis: RJS, DHE, PK, MJS
Interpretation and Writing: RJS, DHE, PK, DHH, MPG, EGK, ML, PG, PLL, KL, ES, MJS, CL
Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the US Centers for Disease Control and Prevention.
The results of this analysis were presented May 17, 2017, at the 15th Conference of the International Society of Travel Medicine, 
Barcelona, Spain.
HHS Public Access
Author manuscript
J Travel Med. Author manuscript; available in PMC 2019 August 01.
Published in final edited form as:
J Travel Med. 2018 August 01; 25(1): . doi:10.1093/jtm/tay053.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods: We performed a descriptive analysis summarizing demographic and travel 
characteristics, and clinical diagnoses among non-US-resident international travelers seen during 
or after travel to the United States at a GeoSentinel clinic from 1 January 1997 through 31 
December 2016.
Results: There were 1,222 ill non-US-resident travelers with 1,393 diagnoses recorded during 
the 20-year analysis period. Median age was 40 years (range 0–86 years); 52% were female. 
Patients visited from 63 countries and territories, most commonly Canada (31%), Germany (14%), 
France (9%), and Japan (7%). Travelers presented with a range of illnesses; skin and soft tissue 
infections of unspecified etiology were the most frequently reported during travel (29 diagnoses, 
14% of during-travel diagnoses); arthropod bite/sting was the most frequently reported after travel 
(173 diagnoses, 15% after-travel diagnoses). Lyme disease was the most frequently reported 
arthropod-borne disease after travel (42, 4%). Nonspecific respiratory, gastrointestinal and 
systemic infections were also among the most frequently reported diagnoses overall. Low-
frequency illnesses (<2% of cases) made up over half of diagnoses during travel and 41% of 
diagnoses after travel, including 13 cases of coccidioidomycosis and mosquito-borne infections 
like West Nile, dengue, and Zika virus diseases.
Conclusions: International travelers to the United States acquired a diverse array of mostly 
cosmopolitan infectious diseases, including nonspecific respiratory, gastrointestinal, dermatologic, 
and systemic infections comparable to what has been reported among travelers to low- and middle-
income countries. Clinicians should consider the specific health risks when preparing visitors to 
the United States and when evaluating and treating those who become ill.
INTRODUCTION
The annual number of international tourist arrivals may reach 1.8 billion by 2030.1 As 
international travel increases, travelers are increasingly acquiring infectious diseases not 
endemic in their home countries and may act as sentinels for outbreaks, spreading infectious 
diseases within a destination country, the next country on a traveler’s itinerary or the 
travelers’ own country after returning home.2 Increased globalization has brought an influx 
of international travelers to regions of the world with emerging economies, and best 
estimates of travel-related illness in international travelers have predominantly reflected 
populations of travelers from highly developed countries visiting low- or middle-income 
countries.3 Though more people are traveling to the developing world than ever before, it 
can be easy for travelers and health care professionals to overlook Western destinations as a 
perceived low risk for infectious disease, yet international travel to and within the developed 
world has only increased.
In 2015, 9 of the top 10 international destinations identified by the United Nations World 
Tourism Organization were in North America or Europe. Combined, these destinations 
accounted for 454.5 million tourist arrivals.1 In the United States specifically, 77.5 million 
international tourists visited in 2015, the most ever recorded. Despite being the second 
largest international tourist destination overall (only France sees larger volumes), few 
sources describe travelers to the United States and the spectrum of illnesses they may 
acquire. This gap in knowledge may impact the health care received by ill travelers who seek 
care both during travel in the United States and after travel once they return home. 
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Familiarity with the illnesses seen in international travelers to the United States can inform 
the development of appropriate pre-travel messages and the medical management of ill 
international travelers. We describe the demographic and travel characteristics, and the 
clinical diagnoses, of non-US-resident international travelers who acquired an illness in the 
United States and presented to clinics in the GeoSentinel Global Surveillance Network.
METHODS
Data source
GeoSentinel is a global clinician-based sentinel surveillance system, established in 1995 as a 
collaboration between the Centers for Disease Control and Prevention (CDC) and the 
International Society of Travel Medicine (ISTM). It consists of 70 specialized travel and 
tropical medicine clinics in 30 countries, mostly affiliated with academic medical centers. 
All sites have experience diagnosing and treating patients with travel-related infectious 
diseases and contribute systematic surveillance data on international travelers and migrants 
seen for a travel-related illness. Analysis of GeoSentinel surveillance data has been approved 
as non-research by a CDC human subjects advisor.
Inclusion and exclusion criteria
Records with at least one confirmed or probable diagnosis among nonmigrant, non-US-
resident international travelers exposed in the United States, as designated by the treating 
clinician, and seen during or after travel at a GeoSentinel clinic in either the United States or 
their country of residence from 1 January 1997 through 31 December 2016 were included in 
this analysis. Data were extracted on traveler demographics (i.e. sex, age, country of 
residence), trip details (i.e. travel duration, travel reason, destinations), and clinical 
information (i.e. date of clinic visit, inpatient or outpatient status, if there was a pre-travel 
consultation with a health care provider, and other diagnoses). The proportion who attended 
a pre-travel consultation was determined among those who visited the United States as their 
only destination country to better approximate those who received care specifically for the 
United States and not another country on the traveler’s itinerary. GeoSentinel first started 
collecting data on pre-existing conditions (e.g. pregnancy, HIV infection, 
immunosuppressing/immunomodulating agents) in March 2013. Consequently, only a subset 
of records had this data available for analysis. We performed descriptive analyses of 
demographic and travel characteristics and diagnoses using SAS Enterprise Guide 7.1 (Cary, 
NC, USA).
RESULTS
There were 1,222 ill non-US-resident travelers with 1,393 diagnoses reported to GeoSentinel 
with travel to the United States during the analysis period. The median age of patients was 
40 years (range 0–86 years); 52% were female (Table 1). Patients visited from 63 countries 
and territories, most commonly Canada (31%), Germany (14%), France (9%), Japan (7%), 
the United Kingdom (4%), Israel (4%), Hong Kong (4%), Switzerland (3%), and Singapore 
(3%). The majority traveled for the purpose of tourism (82%) or business (14%). The 
median travel duration was 14 days (range 1–2,584 days). Among 959 who traveled to the 
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United States and no other destination, 913 had information on pre-travel consultation 
attendance; 81 (9%) attended a pre-travel health consultation. Of the 1,222 patients with 
illness acquired in the United States, 177 (14%) were seen during travel and 1,045 (86%) 
were seen after travel (Table 1).
During travel
Among the 177 patients seen during travel in the United States, 213 diagnoses were 
reported. Nonspecific skin and soft tissue infections were most frequent (29 diagnoses, 14% 
of all diagnoses made during travel), followed by acute gastrointestinal illnesses of 
unspecified etiology (15, 7%), and pneumonia of unspecified etiology (14, 7%) (Table 2A). 
One hundred thirteen (64%) patients seen during travel were hospitalized, including seven 
with sepsis. Of 69 patients with an illness acquired in the United States and seen at a US 
GeoSentinel site since March 2013 when data on pre-existing conditions began being 
collected, 23 (33%) were reported to have at least one such pre-existing condition; all were 
hospitalized. Three deaths were reported: one in a person with pneumonia who subsequently 
died of an unspecified acute cardiac event; one in a person with a pulmonary embolism and 
one in a cancer patient with pre-existing peritonitis who died in the hospital from sepsis.
After travel
Among the 1,045 patients seen after travel to the United States, 1,393 diagnoses were 
reported. The most frequent was arthropod bite/sting (173 diagnoses, 15% of all diagnoses 
made after travel); 81 (47%) of which were tick bites. This was followed by influenza-like 
illness (ILI, 66, 6%), upper respiratory tract infection (URI, 54, 5%), acute gastrointestinal 
illnesses of unspecified etiology (53, 4%), and skin and soft tissue infections of unspecified 
etiology (53, 4%). (Table 2B). Sixteen percent of after-travel patients were hospitalized, 
primarily with respiratory infections. There were no deaths. Respiratory infections including 
ILI, URI, influenza, and pneumonia combined accounted for 204 (17%) diagnoses made 
after travel overall, however 60% of these infections were reported in 1 year, 2009 (Figure 
1). Forty-seven (71%) of 66 of the ILI diagnoses, 42/52 (81%) of the influenza diagnoses, 
26/54 (48%) of the URI diagnoses, and 7/32 (22%) of the pneumonia diagnoses were 
recorded after travel in 2009.
Lyme disease was the most frequently reported arthropod-borne disease, diagnosed in 42 
travelers; 18 were diagnosed with early or acute Lyme, 24 with late stage Lyme. No other 
clinical information was available. Of the 42 Lyme cases, 35 (83%) traveled to the United 
States only; a more specific place of exposure was available for 21 (57%) travelers: New 
York (6), Massachusetts (4), Wisconsin (3), Maine (2), Maryland (2), New Jersey (2), 
Minnesota (1), and Vermont (1).
Notable low-frequency diagnoses
Low-frequency illnesses (<2% cases) made up 51% of diagnoses made during travel and 
41% of diagnoses made after travel. Non-Lyme tick-borne diseases were observed in three 
travelers. Two Germans presented with unspecified tick-borne spotted fever rickettsioses, 
one in 2004 and the other in 2014, and a Canadian with ehrlichiosis was reported in 2014. 
Mosquito-borne arboviral diseases were also observed, including dengue virus (DENV; three 
Stoney et al. Page 4
J Travel Med. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
patients), West Nile virus (WNV; two patients), and Zika virus (ZIKV; one patient) 
infections. No chikungunya virus (CHIKV) infections were reported. The three patients with 
DENV infections had exposure times and places consistent with known past focal outbreaks 
in the United States, including south Florida (one German traveler; 2013) and Hawaii (two 
Canadian travelers; 2015). Of the two patients with WNV infection, one was hospitalized in 
the United Kingdom after their return. The ZIKV infection was in a 30-year-old Israeli 
female who visited Miami, Florida, in August 2016.
Coccidioidomycosis was reported in 13 patients seen post-travel, 4 (31%) of whom were 
hospitalized. The median age of coccidioidomycosis patients was 61 years (range 0–78 
years). Of nine coccidioidomycosis patients with information available, eight travelers were 
exposed in Arizona and one in California.
Clostridium difficile infection was reported in six travelers: three during travel (all 
hospitalized) and three after travel (two hospitalized). Of those seen during travel, all had 
visited Florida and presented 1 week to 5 months after arrival in the United States, two were 
also diagnosed with lobar pneumonia. Of the two hospitalized after return, one was a 72-
year-old Swedish male who visited Orlando, Florida, for 29 days in the summer of 2013 and 
presented with other comorbidities including a skin and soft tissue infection, vancomycin-
resistant enterococci and sepsis, and the other was a 57-year-old Canadian who visited the 
United States for 12 days in September 2014.4
DISCUSSION
We highlight the most frequently reported, and some noteworthy but less frequent diagnoses 
in GeoSentinel, among non-US residents visiting the United States from 1997 through 2016. 
Overall, most patients in the study were tourists and acquired a diverse array of mostly 
cosmopolitan infectious diseases, including nonspecific respiratory, gastrointestinal, 
dermatologic, and systemic infections comparable to what has been reported among 
travelers to other international destinations, including the tropics.5,6 Nonspecific respiratory 
infections were among the most frequently reported illnesses of ill-returned travelers from 
the United States, however, 60% of nonspecific respiratory infections were diagnosed in 
2009, likely due to increased screening among some GeoSentinel sites for influenza A 
H1N1. Acute gastrointestinal illnesses and skin and soft tissue infections were also 
frequently diagnosed, though each accounted for only 5% of diagnoses made after travel 
overall. Similar to studies of persons traveling to lower-income countries,6,7,8 it is important 
for travelers and health care professionals to recognize that travel-related respiratory, 
gastrointestinal, and dermatologic illnesses also occur among international travelers to 
developed countries9 and may vary in relation to specific traveler characteristics, including 
travel purpose, diet, activities during travel, and the health profile of the individual traveler.
10
Some notable, less frequently encountered but potentially severe diseases endemic to the 
United States also occurred. Arthropod exposure, reflecting tick bites and tick-borne disease 
diagnoses (e.g. Lyme disease), was diagnosed more often than other conditions. Ticks 
transmit the greatest diversity of arthropod-borne pathogens in the United States and are 
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responsible for the largest number of vector-borne diseases there.11,12 In recent decades, the 
reported number of notifiable tick-borne diseases has steadily increased as the geographic 
distribution of many ticks and tick-borne diseases has expanded and new tick-borne 
pathogens have emerged.11 Human vaccines for tick-borne diseases that occur in the United 
States are lacking.11 Therefore, travelers to the United States should avoid tick habitats 
whenever possible. If that is not possible, travelers should use tick repellents containing 
DEET, picaridin, IR3535, oil of lemon eucalyptus, para-menthane-diol or 2-undecanone on 
exposed skin, use products containing 0.5% permethrin to treat clothing, check for ticks 
daily and properly remove them, if found.13
Lyme disease is the most frequently reported vector-borne disease in the United States and 
was diagnosed in 42 patients seen after travel.14 Incidence rates are underreported in the 
United States, but the true magnitude is estimated at 240,000 to 440,000 cases annually.11 
Approximately 96% of Lyme disease cases have been reported from 14 states in the 
Northeast, mid-Atlantic, and upper Midwest, though evidence suggests that endemic foci 
have expanded over time.14 The expansion of areas with high incidence mirrors the 
geographic expansion of Ixodes scapularis in the eastern United States; infection is less 
common in the far western United States, where I. pacificus is the vector.11
Arboviral diseases, including WNV, DENV, and ZIKV infections occurred in travelers to the 
United States. WNV is the leading cause of domestically acquired arboviral disease in the 
United States, and is primarily spread by mosquito species of the Culex genus.15 During 
2015, 2,282 cases of domestic arboviral disease were reported to CDC; 2,175 (95%) were 
WNV cases. Most human infections are asymptomatic; symptomatic infections commonly 
manifest as a systemic febrile illness, and, less commonly, as neuroinvasive disease. DENV 
and ZIKV infections were also reported, but only from known outbreak areas. Unlike WNV, 
Aedes aegypti and A. albopictus species are known to variably transmit DENV, ZIKV, and 
CHIKV. Although Aedes species are common in the southern United States, DENV is 
endemic in northern Mexico, and the US population is largely immune-naïve, the lack of 
DENV transmission in the continental United States likely reflects more limited contact 
between people and Aedes species mosquitoes than occurs where transmission is more 
common.16 Preventing mosquito bites is important when traveling in the United States, 
especially in Hawaii and the southern states.
Coccidioidomycosis is endemic in the southwestern United States and is underreported.17 
Evidence suggests coccidioidomycosis causes 15–29% of community-acquired pneumonia 
in certain highly endemic areas.18 Of states endemic for coccidioidomycosis, the 2016 
incidence was highest in Arizona (89.3 per 100,000 population) and California (13.7 per 
100,000 population).19 Some groups may be at higher risk for developing severe forms of 
coccidioidomycosis, including immunocompromised individuals, pregnant women, 
individuals with diabetes, persons of African or Filipino descent, and adults in older age 
groups.17 Travelers can prevent infection by avoiding areas where Coccidioides spores may 
be present, such as construction or excavation sites, and by avoiding activities that involve 
close contact with soil or dust, including yard work, gardening, and digging.17,18,19 Health 
care providers should be aware of this increasingly common infection when treating persons 
with ILI or pneumonia who live in or have traveled to endemic areas.18
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Though the majority of patients were seen after travel with an acute illness, a 
disproportionate number of patients were hospitalized during travel, many with pre-existing 
health conditions. In addition, three travelers died during their visit to the United States, 
while there were no records of deaths among those who visited the United States and were 
seen at a clinic after travel. Noninfectious conditions are known to cause considerable 
morbidity and mortality among international travelers,20 and unspecified chronic health 
conditions have been associated with health problems experienced during and after travel, 
including hospitalization.6 Medical advances are enabling individuals with chronic health 
conditions opportunities to travel despite their health limitations,21 but travelers with these 
problems may have unique health risks making them more susceptible to illness or injury 
while traveling, leading to exacerbation of their underlying conditions.22,6
This analysis has several limitations. First, GeoSentinel surveillance data are not population-
based, so disease risks and rates cannot be determined. Further, GeoSentinel sites are travel/
tropical medicine focused, therefore our findings may not be representative of all 
international travelers. Other health problems (e.g. traumatic injuries and chronic disease 
exacerbations) may be underrepresented. GeoSentinel does not routinely collect detailed 
information on traveler comorbidities and only began collecting limited information on this 
parameter in 2013. As such, the number of travelers with underlying chronic health 
conditions could not be determined. Death is not well captured in the GeoSentinel 
surveillance network; data are collected from a single time point and may not capture a 
death that follows the initial clinic visit. Similarly, GeoSentinel has not routinely collected 
information on antibiotic exposure among travelers, either during travel or since return from 
travel. Diagnostic codes in GeoSentinel include specific etiologic diagnoses and nonspecific 
syndromic diagnoses, and nonspecific diagnosis codes are assigned when an etiologic 
diagnosis cannot be determined or are not pursued. Finally, GeoSentinel relies on the 
judgement of its clinicians for assignment of diagnoses and place of exposure; diagnostic 
testing information that could be used to validate assigned diagnoses was not routinely 
collected during the analysis period.
Travelers to the United States should be aware of the diseases they may acquire, paying 
particular attention to vector-borne infections. Practicing appropriate arthropod avoidance 
measures may help prevent these infections. Persons with chronic underlying conditions 
should take ample supplies of their medications and plan for unanticipated medication 
shortfalls or possible chronic disease exacerbations. Clinicians, including primary care 
practitioners, should consider the specific health risks when preparing visitors to the United 
States and when evaluating and treating those who become ill.
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Figure 1. 
During- and after-travel diagnoses among non-US-resident travelers visiting the United 
States, GeoSentinel, 1997–2016.
*In 2009, 211 diagnoses were reported after travel, the most of any single year in the 
analysis period. Screening practices for influenza A (H1N1) increased in 2009 compared to 
all other years in the analysis period, and may have contributed to the increase. The most 
frequently reported diagnoses that year were influenza-like illness (ILI n=47; 22% of 2009 
diagnoses and 71% of all ILI diagnoses for the study period), influenza (n=42; 20% of 2009 
diagnoses and 81% of all influenza diagnoses), upper respiratory infection (URI) of 
unspecified etiology (n=26; 12% of 2009 diagnoses and 48% of all unspecified URI 
diagnoses), and pneumonia of unspecified etiology (n=32, 3% of 2009 diagnoses and 22% 
of all unspecified pneumonia diagnoses).
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